GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: https://greenlightbiosciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2022 | $4.00 | Buy | Canaccord Genuity |
| 10/14/2022 | $5.50 | Outperform | Credit Suisse |
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)
Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00
Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50